Alcon: UBS nudges up TP
(CercleFinance.com) - UBS has confirmed its "buy" recommendation on Alcon shares, with its target price raised slightly (from 92 CHF to 93.
5 CHF), a new TP that represents 12% upside potential for the Swiss ophthalmology laboratory's shares.
Meetings with the CEO have made us more optimistic about product launches in 2025, although short-term investments in general and administrative costs will be necessary to support strong revenue growth, the broker says.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
5 CHF), a new TP that represents 12% upside potential for the Swiss ophthalmology laboratory's shares.
Meetings with the CEO have made us more optimistic about product launches in 2025, although short-term investments in general and administrative costs will be necessary to support strong revenue growth, the broker says.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.